Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $12.31 USD
Change Today +0.27 / 2.24%
Volume 1.3M
RPTP On Other Exchanges
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

7 Hamilton Landing

Suite 100

Novato, CA 94949

United States

Phone: 415-408-6200

Fax: 415-382-8002

Raptor Pharmaceutical Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. Products The company’s first product, PROCYSBI (cysteamine bitartrate) delayed-release capsules received marketing approval from the U.S. Food and Drug Administration (FDA) in April 2013 for the management of nephropathic cystinosis in adults and children six years and older. In September 2013, the European equivalent, PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), received a Community or EU marketing authorization from the European Commission (EC), as an orphan medicinal product for the management of proven nephropathic cystinosis. The company commenced commercial sales of PROCYSBI in the U.S. in June 2013. PROCYSBI is an approved therapy for the management of nephropathic cystinosis, a rare, life-threatening metabolic lysosomal storage disorder that causes the rapid, toxic accumulation of cystine in all cells, tissues and organs in the body. PROCYSBI capsules contain cysteamine bitartrate in the form of microspheronized beads that are individually coated to create delayed and extended-release properties, allowing patients to maintain consistent therapeutic systemic drug levels over a 12-hour dosing period. Randomized controlled clinical trials and extended treatment with PROCYSBI therapy demonstrated consistent cystine depletion as monitored by levels of the biomarker (and surrogate marker), white blood cell cystine. RP103 as a treatment for Huntington's disease (HD) RP103, enteric-coated delayed-release cysteamine bitartrate, is being evaluated as a potentially disease modifying treatment for HD. Other Clinical-Stage Product Candidates Convivia for aldehyde dehydrogenase Deficiency: The company is in the process of developing Convivia, its proprietary oral formulation of 4-methylpyrazole, or 4-MP, for the potential treatment of acetaldehyde toxicity resulting from aldehyde dehydrogenase deficiency. The company owns the intellectual property portfolio pertaining to Convivia, including method of use and formulation patents. In 2010, the company granted a license to commercialize Convivia in Taiwan to Uni Pharma Co., Ltd. Under this agreement, Uni Pharma Co., Ltd. is responsible for clinical development, registration and commercialization of Convivia in Taiwan. Preclinical Product Candidates The company’s preclinical programs include its cysteamine dioxygenase, or ADO, program, to improve treatment of diseases for which cysteamine is therapeutic and its HepTide program to treat hepatocellular carcinoma and other cancers susceptible to induced lysosomal storage. Trademarks The trademark ‘Raptor’ is registered in the U.S. and the EU, and applied for in certain other countries. The company also owns applications and registrations for various other marks in the U.S. and certain countries throughout the world. Research and Development As of December 31, 2013, the company incurred approximately $29.2 million on research and development expenses. History Raptor Pharmaceutical Corp. was founded in 2006. The company was incorporated under the laws of the state of Delaware.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RPTP:US $12.31 USD +0.27

RPTP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $41.19 USD -0.56
Illumina Inc $206.08 USD -2.54
View Industry Companies

Industry Analysis


Industry Average

Valuation RPTP Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RAPTOR PHARMACEUTICAL CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at